Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model

Hamilton, P, Kanigicherla, D, Venning, M et al. (2 more authors) (2018) Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model. Nephrology Dialysis Transplantation, 33 (12). pp. 2145-2155. ISSN 0931-0509

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: (c) 2018, The Author(s). Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. This is a pre-copyedited, author-produced version of an article accepted for publication in Nephrology Dialysis Transplantation following peer review. The version of record, 'Hamilton, P, Kanigicherla, D, Venning, M, Brenchley, P, and Meads, D (2018). Rituximab versus the modified Ponticelli regimen in the treatment of primary membranous nephropathy: a Health Economic Model. Nephrology Dialysis Transplantation,' is available online at: https://doi.org/10.1093/ndt/gfy049
Keywords: Markov model; membranous nephropathy; nephrotic syndrome
Dates:
  • Published: 1 December 2018
  • Accepted: 28 January 2018
  • Published (online): 29 March 2018
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Leeds Institute of Health Sciences (Leeds) > Academic Unit of Health Economics (Leeds)
Depositing User: Symplectic Publications
Date Deposited: 03 May 2018 14:49
Last Modified: 29 Mar 2019 01:43
Status: Published
Publisher: Oxford University Press
Identification Number: https://doi.org/10.1093/ndt/gfy049
Related URLs:

Share / Export

Statistics